Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease Insights From the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence Registry by Hira, Ravi S. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 2 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 0 . 0 3 5ORIGINAL INVESTIGATIONSFrequency and Practice-Level Variation in
Inappropriate Aspirin Use for the Primary
Prevention of Cardiovascular Disease
Insights From the National Cardiovascular Disease Registry’s
Practice Innovation and Clinical Excellence RegistryRavi S. Hira, MD,* Kevin Kennedy, MS,y Vijay Nambi, MD, PHD,z* Hani Jneid, MD,z* Mahboob Alam, MD,*
Sukhdeep S. Basra, MD, MPH,* P. Michael Ho, MD, PHD,x Anita Deswal, MD, MPH,z* Christie M. Ballantyne, MD,*
Laura A. Petersen, MD, MPH,zk{ Salim S. Virani, MD, PHDzk*JACC JOURNAL CMEThis article has been selected as the month’s JACC Journal CME activity.
Accreditation and Designation Statement
The American College of Cardiology Foundation (ACCF) is accredited by
the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME activity for a maximum
of 1 AMA PRA Category 1 Credit(s). Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Method of Participation and Receipt of CME Certiﬁcate
To obtain credit for JACC CME, you must:
1. Be an ACC member or JACC subscriber.
2. Carefully read the CME-designated article available online and in this
issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions
provided must be answered correctly to obtain CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certiﬁcate electronically by
following the instructions given at the conclusion of the activity.
CME Objective for This Article: After reading this article, the reader should
be able to: 1) state the current recommendations for aspirin use in pri-
mary prevention of cardiovascular disease (CVD); 2) identify, using car-
diovascular disease risk algorithms, patients in whom the bleeding use
associated with aspirin therapy may outweigh its anti-ischemic beneﬁts;
and 3) describe practice-level variation in potentially inappropriate use of
aspirin therapy for primary CVD prevention.From the *Section of Cardiology, Department of Medicine, Baylor College
Institute, Saint Luke’s Hospital, Kansas City, Missouri; zMichael E. DeBake
xUniversity of Colorado, Denver, Colorado; kHealth Policy, Quality and Infor
Medical Center, Health Services Research and Development Center for Inno
Services Research, Department of Medicine, Baylor College of Medicine, HouCME Editor Disclosure: JACC CME Editor Ragavendra Baliga, MD, FACC,
has reported that he has no ﬁnancial relationships or interests
to disclose.
Author Disclosures: Dr. Nambi was a national monitor for a study spon-
sored by Anthera Inc.; coinvestigator on a provisional patent ﬁled by
Baylor College of Medicine and Roche Diagnostics on the use of bio-
markers in heart failure prediction; performed research collaboration
with GE and Tomtec; and is a member of the regional advisory board for
Sanoﬁ. Dr. Alam is a member of the advisory board for AstraZeneca. Dr.
Ballantyne has received grant/research support (all signiﬁcant and all
paid to the institution [not individual]) from Abbott, Amarin, Amgen,
Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pﬁzer, Regeneron, Roche,
Sanoﬁ-Synthélabo, National Institutes of Health, and the American Heart
Association; and served as a consultant for Abbott, Aegerion, Amarin,
Amgen, Cerenis, Esperion, Genzyme, Kowa, Merck, Novartis, Pﬁzer,
Resverlogix, Regeneron, Roche, and Sanoﬁ-Synthélabo (the funding from
Merck and Pﬁzer were signiﬁcant, and others were moderate in amount).
Dr. Virani has received grant/research support (all signiﬁcant and paid to
the institution [not individual]) from the Department of Veterans Affairs,
the American Diabetes Association, and the American Heart Association.
All other authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
Medium of Participation: Print (article only); online (article and quiz).
CME Term of Approval
Issue date: January 20, 2015
Expiration date: January 19, 2016of Medicine, Houston, Texas; yMid America Heart
y Veteran Affairs Medical Center, Houston, Texas;
matics Program, Michael E. DeBakey Veteran Affairs
vations, Houston, Texas; and the {Section of Health
ston, Texas. The views expressed in this article are
Hira et al. J A C C V O L . 6 5 , N O . 2 , 2 0 1 5
Practice Variation in Inappropriate Aspirin Use J A N U A R Y 2 0 , 2 0 1 5 : 1 1 1 – 2 1
112Frequency and Practice-Level Variation in
Inappropriate Aspirin Use for the Primary
Prevention of Cardiovascular Disease
Insights From the National Cardiovascular Disease Registry’s
Practice Innovation and Clinical Excellence RegistryABSTRACTtho
mo
Ro
is
Dr
Am
of
Es
Me
sig
As
the
Lis
Yo
MaBACKGROUND Among patients without cardiovascular disease (CVD) and low 10-year CVD risk, the risks of gastro-
intestinal bleeding and hemorrhagic strokes associated with aspirin use outweigh any potential atheroprotective beneﬁt.
According to the guidelines on primary prevention of CVD, aspirin use is considered appropriate only in patients with
10-year CVD risk $6% and inappropriate in patients with 10-year CVD risk <6%.
OBJECTIVES The goal of this study was to examine the frequency and practice-level variation in inappropriate aspirin
use for primary prevention in a large U.S. nationwide registry.
METHODS Within the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence registry,
we assessed 68,808 unique patients receiving aspirin for primary prevention from 119 U.S. practices. The frequency
of inappropriate aspirin use was determined for primary prevention (aspirin use in those with 10-year CVD risk <6%).
Using hierarchical regression models, the extent of practice-level variation using the median rate ratio (MRR) was
assessed.
RESULTS Inappropriate aspirin use frequency was 11.6% (7,972 of 68,808) in the overall cohort. There was signiﬁcant
practice-level variation in inappropriate use (range 0% to 71.8%; median 10.1%; interquartile range 6.4%) for practices;
adjusted MRR was 1.63 (95% conﬁdence interval [CI]: 1.47 to 1.77). Results remained consistent after excluding 21,052
women age $65 years (inappropriate aspirin use 15.2%; median practice-level inappropriate aspirin use 13.8%; inter-
quartile range 8.2%; adjusted MRR 1.61 [95% CI: 1.46 to 1.75]) and after excluding patients with diabetes (inappropriate
aspirin use 13.9%; median practice-level inappropriate aspirin use 12.4%; interquartile range 7.6%; adjusted MRR 1.55
[95% CI: 1.41 to 1.67]).
CONCLUSIONS More than 1 in 10 patients in this national registry were receiving inappropriate aspirin therapy for
primary prevention, with signiﬁcant practice-level variations. Our ﬁndings suggest that there are important opportunities
to improve evidence-based aspirin use for the primary prevention of CVD. (J Am Coll Cardiol 2015;65:111–21) © 2015 by
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113AB BR E V I A T I O N S
AND ACRONYM S
AHA = American Heart
Association
CHD = coronary heart disease
CI = conﬁdence interval
CVD = cardiovascular disease
MI = myocardial infarction
MRR = median rate ratio
PINNACLE = Practice
Innovation and Clinical
ExcellenceC ardiovascular disease (CVD) has been theleading cause of death in the United Statesfor the past century and is the underlying
cause of death in 32.3% of people (1). Therefore,
emphasis has been placed on the primary and second-
ary prevention of this disease (2). Aspirin use is rec-
ommended for secondary prevention in patients
with pre-existing CVD (3), and it is recommended
for primary prevention in patients without CVD who
have a moderate to high 10-year risk of developing
CVD (2,4). However, in patients without CVD and a
low 10-year CVD risk, there is no proof that aspirin
use is associated with a reduction in adverse cardio-
vascular events. In this primary prevention popula-
tion, the increased risk of gastrointestinal bleeding
and hemorrhagic strokes associated with aspirin use
outweighs any potential beneﬁt from CVD risk reduc-
tion (5).SEE PAGE 122Based on these ﬁndings, the American Heart
Association (AHA) guidelines on primary prevention
of CVD and stroke in 2002 (6) recommended aspirin
for patients with 10-year coronary and stroke
risk $10%. The U.S. Preventive Services Task Force
recommendation on aspirin use for prevention of
CVD from 2009 (4) advised an approach of weighing
the beneﬁt of preventing CVD against the risk of
increased gastrointestinal bleeding and hemorrhagic
strokes, with recommendations to use aspirin if
5-year coronary heart disease (CHD) risk is $3%
(10-year CHD risk of $6%). The recent AHA/Amer-
ican Stroke Association guidelines for primary pre-
vention of stroke in 2011 (7) recommend aspirin use
for primary prevention if 10-year CVD risk is at least
6% to 10% (Class I; Level of Evidence: A). Thus,
aspirin use for primary prevention would be
considered appropriate in patients with 10-year CVD
risk $6%. Given the risk of gastrointestinal bleeding
and hemorrhagic strokes, aspirin use for primary
prevention in patients at low risk of cardiovascular
events (10-year CVD risk <6%) would be potentially
inappropriate.
The U.S. Food and Drug Administration also
recently issued a public advisory against the general
use of aspirin for the primary prevention of heart at-
tacks and strokes (8). This decision followed its denial
of a request to change professional labeling to allow
marketing of aspirin for primary prevention of heart
attacks.
Accordingly, we examined the frequency and
practice-level variation in inappropriate aspirin
use for primary CVD prevention in a national
cohort of patients enrolled in the American Collegeof Cardiology’s National Cardiovascular Dis-
ease Registry’s Practice Innovation and Clin-
ical Excellence (PINNACLE) registry.
METHODS
STUDY POPULATION. The PINNACLE regis-
try, launched in 2008, is a prospective,
ofﬁce-based, outpatient quality improvement
registry of CVD patients seeking care in
U.S. cardiology practices. Site participation
in this initiative is voluntary, with data
collected at the point of care for 100% of pa-
tients with coronary artery disease, heart failure,
atrial ﬁbrillation, and hypertension at each practice.
The majority of sites provide data via electronic
health records (9–14). Periodic global edit checks are
conducted on all records to identify outliers in per-
formance rates and ineligible instance totals before
submission to the Centers for Medicare & Medicaid
Services.
COHORT DEVELOPMENT AND DEFINITIONS. From
the PINNACLE registry, patients receiving aspirin
from 119 practices (21.9% were solo practices)
between January 12, 2008, and June 15, 2013, were
identiﬁed. Because a patient may have had multiple
outpatient visits during the study interval, we used
information from the most recent outpatient visit for
each patient.
Patients were excluded if they were receiving
aspirin for secondary prevention (i.e., history of
myocardial infarction [MI], percutaneous coronary
intervention, coronary artery bypass graft surgery,
peripheral arterial disease, prior stroke, prior tran-
sient ischemic attack, atrial ﬁbrillation, unstable
angina, systemic embolism, heart transplant, prior
cardiovascular surgery) or were receiving concomi-
tant warfarin, clopidogrel, ticlopidine, or an aspirin/
extended-release dipyridamole combination.
Because observational and clinical trial data indi-
cate that a woman’s risk for ischemic stroke typically
exceeds her risk for CHD (15), the 10-year CVD risk (as
opposed to a CHD risk calculator) was evaluated in all
patients. We used the Framingham general CVD risk
assessment tool, which has been well validated. The
variables used in the Framingham 10-year CVD risk
calculator include age, sex, hypertension, diabetes,
cigarette smoking, total and high-density lipoprotein
cholesterol levels, systolic blood pressure, and treat-
ment of hypertension. The outcome calculated is an
individual patient’s 10-year risk of CVD events, which
includes CHD events (coronary death, MI, coronary
insufﬁciency, and angina), cerebrovascular events
(ischemic stroke, hemorrhagic stroke, and transient
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heart failure (16).
OUTCOMES
Inappropriate aspirin use was deﬁned as aspirin
therapy in patients with documentation in the data
collection form of current aspirin use along with a 10-
year risk of a CVD event <6%. All remaining patients
were classiﬁed as appropriately receiving aspirin
therapy for primary prevention. Because aspirin dose
is not routinely collected in the PINNACLE registry,
we evaluated aspirin use as a categorical (yes/no)
variable.
The following outcomes were studied: 1) frequency
of inappropriate aspirin use for primary CVD pre-
vention in the entire registry; and 2) extent of
practice-level variation in inappropriate aspirin use
for primary CVD prevention. We also assessed tem-
poral trends for inappropriate aspirin use for primary
CVD prevention in the PINNACLE registry.
STATISTICAL ANALYSIS. For analyses pertaining to
the frequency of inappropriate use, the number of
patients who were receiving aspirin inappropriately
was divided by the total number of patients who were
receiving aspirin for primary CVD prevention. We
then compared the baseline characteristics between
patients receiving inappropriate versus appropriate
aspirin therapy for primary prevention by using
Student t tests for continuous variables and chi-
square tests for categorical variables. Annual rates
of inappropriate aspirin use since 2008 were then
evaluated.
We subsequently determined inappropriate aspirin
use for each practice with >30 patients receiving
aspirin for primary prevention; descriptive plots were
used for these analyses. The number of patients
receiving inappropriate aspirin therapy at each prac-
tice was divided by the number of patients receiving
aspirin for primary CVD prevention at that practice.
Practice characteristics were then compared, strati-
ﬁed according to practice prescription rates above
and below the median combined rate of inappropriate
aspirin use; Student t tests were used for continuous
variables and chi-square tests were used for categor-
ical variables.
To further examine the extent of practice-level
variation in inappropriate aspirin use, multivariable
hierarchical regression models were constructed to
determine the median rate ratio (MRR) for inappro-
priate aspirin use for primary CVD prevention. Two-
level hierarchical models were used to adjust for
clustering of patients within practices, with theindividual practices modeled as a random effect and
patient characteristics as ﬁxed effects within each
practice (17). This approach allowed us to control for
confounding between practices because the use of
hierarchical models ensured that patients with similar
baseline characteristics were compared with each
other from the same practice. The following covariates
were included in the model: provider type (physician
vs. nurse practitioner) and practice region (West,
Northeast, Midwest, and South). The resultant MRR
provides an estimate of the effect size of the practice
on the outcome and can be interpreted as the likeli-
hood that 2 randomly chosen practices would differ
in treatment of “identical” patients. For example, an
MRR of 1 suggests no practice-level variation and
similar treatment at 2 randomly chosen practices for
identical patients, whereas an MRR of 1.50 suggests a
50% likelihood of differing treatment (e.g., inappro-
priate vs. appropriate) for identical patients receiving
care at 2 randomly chosen practices. Based on previ-
ous literature, an MRR >1.2 indicates clinically sig-
niﬁcant practice-level variation (10,18).
The 2011 AHA update to the guideline for CVD pre-
vention in women (15) recommends aspirin use for
primary prevention as Class IIa (Level of Evidence: B)
for use in women$65 years of age, when the beneﬁt of
ischemic stroke and MI prevention is likely to
outweigh the risk of gastrointestinal bleeding and
hemorrhagic stroke. In addition, aspirin for primary
prevention was recommended by the American Dia-
betes Association (19) for patients with diabetes in
patientswhowere>40 years of agewith additional risk
factors. Lastly, statin use can alter cholesterol levels
and, therefore, 10-year CVD risk. Given these recom-
mendations, sensitivity analyses were also performed
by excluding: 1) women $65 years of age; 2) patients
with diabetes; and 3) patients receiving statin therapy.
The frequency and practice-level variation of inap-
propriate aspirin use were then re-evaluated.
As secondary analyses, we also examined whether
the frequency of inappropriate aspirin use at a prac-
tice was associated with either the overall frequency
of aspirin use or the frequency of aspirin use for
secondary CVD prevention at that practice by using
the Spearman correlation coefﬁcient. For all analyses,
the null hypothesis was evaluated with a 2-sided
signiﬁcance level of 0.05. All analyses were per-
formed by using SAS version 9.3 (SAS Institute, Inc.,
Cary, North Carolina).
RESULTS
The study ﬂow diagram is shown in Figure 1. From the
PINNACLE registry, we evaluated 9,538,255 patient
FIGURE 1 Details of Cohort Development
Total Encounters:
1/12/08—6/15/13
N=9,538,255
Exclusion: Encounters not
receiving Aspirin
N=4,148,941
Encounters receiving 
Aspirin
N=5,389,314
Exclusion: Duplicate
encounter
N=4,081,141
Unique patients receiving
Aspirin
N=1,308,173
Patients receiving Aspirin
for primary prevention
N=254,339
Exclusion: Missing variables
N=185,531
Final analytic cohort
N=68,808
Appropriate use
N=60,836
Inappropriate use
N=7972 (11.6%)
Exclusion: History MI, History PCI, History CABG, PAD, 
stroke/TIA, Atrial fibrillation, Unstable angina,
Systemic embolism, Heart transplant, prior CV surgery,
use of warfarin, clopidogrel, ticlodipine, aggrenox
N=1,053,834
The study population was initially selected to allow analysis of prevalence and temporal
trends of inappropriate aspirin use for primary prevention of cardiovascular disease (CVD).
Patients were excluded for duplicate encounters, receiving aspirin for secondary preven-
tion, or inability to calculate 10-year CVD risk due to missing variables. Patients were then
classiﬁed as receiving aspirin inappropriately for primary CVD prevention if 10-year CVD
risk was <6% and those receiving aspirin appropriately if 10-year CVD risk was $6%.
CABG ¼ coronary artery bypass graft; CV ¼ cardiovascular; MI ¼ myocardial infarction;
PAD ¼ peripheral arterial disease; PCI ¼ percutaneous coronary intervention;
TIA ¼ transient ischemic attack.
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115encounters between January 12, 2008, and June 15,
2013. After exclusions due to patients not receiving
aspirin, multiple encounters for the same patient,
history of MI, percutaneous coronary intervention,
coronary artery bypass graft surgery, peripheral
arterial disease, prior stroke or transient ischemic
attack, atrial ﬁbrillation, unstable angina, systemic
embolism, heart transplant, prior cardiovascular
surgery, or because these patients were receiving
concomitant warfarin, clopidogrel, ticlopidine, or
aspirin/extended-release dipyridamole, a total of
254,339 patients were determined to be receiving
aspirin for primary prevention. Of these patients,
10-year CVD risk could not be calculated in 185,531
(72.9%) due to missing variables. Thus, the ﬁnal
cohort included 68,808 patients receiving aspirin for
primary CVD prevention in whom the 10-year CVD
risk could be calculated.
Of the total cohort, 7,972 patients (11.6%) had a
calculated 10-year CVD risk <6% and were thus
receiving aspirin inappropriately. The majority of
these patients were female (79.7%); the frequency of
inappropriate aspirin use was 16.6% (6,353 of 38,349)
among female subjects and 5.3% (1,619 of 30,459)
among male subjects. The annual trend of inappro-
priate aspirin use decreased from 14.5% in 2008 to
9.1% in 2013 (Figure 2).
Baseline characteristics of patients with inappro-
priate aspirin use compared with those with appro-
priate use are summarized in Table 1. Patients
receiving aspirin inappropriately were younger
(49.9 vs. 65.9 years). A larger proportion of patients
in the appropriate group were male; had diabetes,
hypertension, or dyslipidemia; and were smokers.
These ﬁndings were not surprising because increased
age and male sex carry a higher weight while calcu-
lating 10-year CVD risk using the Framingham general
CVD risk calculator. Patients receiving aspirin for
an inappropriate indication were less likely to be
prescribed angiotensin-converting enzyme inhi-
bitors, angiotensin receptor blockers, beta-blockers,
calcium channel blockers, diuretics, or statins. Mean
10-year CVD risk in the inappropriate aspirin group
was 4.0% versus 24.5% in the appropriate group
(p < 0.001).
Practice-level variation in inappropriate aspirin
use is shown in the Central Illustration. The median
practice-level frequency for inappropriate aspirin use
was 10.1%. There was signiﬁcant practice-level vari-
ation in inappropriate aspirin use, with a range of 0%
to 71.8% (interquartile range: 6.4%). MRR for inap-
propriate aspirin use was 1.63 (95% conﬁdence
interval [CI]: 1.47 to 1.77), indicating signiﬁcant vari-
ation in inappropriate aspirin use across practices.The MRR of 1.63 suggests that between 2 “identical”
patients treated at 2 randomly chosen practices, 1
patient was 63% more likely to receive aspirin inap-
propriately than another patient with similar charac-
teristics because of the practice where they were
receiving care.
To further evaluate practice characteristics associ-
ated with inappropriate aspirin use, practices above
or below the median inappropriate aspirin use were
evaluated. Interestingly, the number of physicians or
the number of providers in a practice and the dura-
tion of participation in the PINNACLE registry were
TABLE 1 Comparison of Baseline Characteristics of Patients With
Inappropriate or Appropriate Aspirin Use for Primary CVD
Prevention
Inappropriate
(n ¼ 7,972)
Appropriate
(n ¼ 60,836) p Value
Age, yrs 49.9  11.3 65.9  11.8 <0.001
Male 1,619 (20.3) 28,840 (47.4) <0.001
Race
White 3,936 (49.4) 32,534 (53.5) <0.001
Black 535 (6.7) 3,593 (5.9) <0.001
Hispanic 106 (1.3) 644 (1.1) <0.001
Provider type 0.132
Physician 7,591 (96.2) 57,788 (96.5)
Nurse practitioner 251 (3.2) 1,679 (2.8)
Other 52 (0.7) 438 (0.7)
Insurance type*
Private 5,444 (68.3) 35,347 (58.1) <0.001
Medicare 1,130 (14.2) 30,467 (50.1) <0.001
None 521 (6.5) 2,239 (3.7) <0.001
Comorbidities
Diabetes 344 (4.3) 13,753 (22.6) <0.001
Hypertension 4,689 (58.8) 51,817 (85.2) <0.001
Dyslipidemia 5,465 (68.6) 50,136 (82.4) <0.001
Tobacco use 1,631 (20.5) 30,024 (49.4) <0.001
Medications
Angiotensin-converting
enzyme inhibitor
1,474 (18.5) 22,428 (36.9) <0.001
Angiotensin receptor
blocker
808 (10.1) 13,588 (22.3) <0.001
Beta-blocker 2,406 (30.2) 28,168 (46.3) <0.001
Calcium-channel blocker 726 (9.1) 13,738 (22.6) <0.001
Diuretic 1,662 (20.8) 23,846 (39.2) <0.001
Statin 3,789 (47.5) 37,104 (61.0) 0.001
Values are mean  SD or n (%); percentages were calculated from available data.
*Patients can have >1 type of insurance.
CVD ¼ cardiovascular disease.
FIGURE 2 Annual Trend of Inappropriate Aspirin Use in the
PINNACLE Registry
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Inappropriate aspirin use
The annual inappropriate aspirin use for primary prevention
decreased from 14.5% in 2008 to 9.1% in 2013. PINNACLE ¼
Practice Innovation and Clinical Excellence.
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116higher in practices above the median compared with
the practices below the median practice-level rates of
inappropriate aspirin use (Table 2).
There was modest regional variation noted in
inappropriate aspirin use. The proportion of patients
receiving inappropriate aspirin therapy for primary
CVD prevention in the Northeast, Midwest, South,
and West were 11.4%, 12.2%, 11.3%, and 10.6%,
respectively (p < 0.001).
Our results remained consistent after excluding
21,052 women $65 years of age: inappropriate aspirin
use 15.2% (range 2.0% to 29.4%); median practice-
level inappropriate aspirin use 13.8% (interquartile
range: 8.2%); and adjusted MRR 1.61 (95% CI: 1.46
to 1.75). Similar results were found after excluding
14,097 patients with diabetes: inappropriate aspirin
use 13.9% (range 0% to 71.8%); median practice-level
inappropriate aspirin use 12.4% (interquartile range:
7.6%); and adjusted MRR 1.55 [95% CI: 1.41 to 1.67).
After excluding 40,893 patients receiving statin
therapy, results were as follows: inappropriate aspirin
use 14.9% (range 2.4% to 29.6%); median practice-
level inappropriate aspirin use 14.5% (interquartile
range: 7.7%); and adjusted MRR 1.44 (95% CI: 1.31
to 1.55).
There was no correlation between a practice’s
frequency of inappropriate aspirin use for primary
CVD prevention and the overall frequency of aspirin
use at that practice (Spearman correlation coefﬁcient0.112; p ¼ NS). Similarly, there was no correlation
between a practice’s frequency of inappropriate
aspirin use for primary prevention and its use of
aspirin therapy for secondary prevention (Spearman
correlation coefﬁcient 0.025) at that practice
(p ¼ NS).
DISCUSSION
Our data provide an overview of contemporary use of
aspirin for primary prevention in a national registry
of U.S ofﬁce-based patients with CVD. We found that
11.6% of patients were receiving aspirin for primary
CVD prevention with a 10-year CVD risk <6%. There
was also signiﬁcant practice-level variation, with an
MRR of 1.63 (Central Illustration). Our results provide
an important benchmark for inappropriate aspirin use
for primary CVD prevention in contemporary outpa-
tient U.S. practices.
CENTRAL ILLUSTRATION U.S. Cardiology Practice-Level Variation in
Inappropriate Aspirin Use
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Inappropriate aspirin use frequency was 11.6% (7,972 of 68,808) in the overall cohort.
There was signiﬁcant practice-level variation in inappropriate use (range 0% to 71.8%;
median 10.1%; interquartile range: 6.4%) for practices; adjusted median rate ratio was
1.63 (95% conﬁdence interval: 1.47 to 1.77).
TABLE 2 Practice Characteristics by Median Rates of Inappropriate Aspirin Use
Inappropriate Aspirin
Use Below Median
(n ¼ 43)
Inappropriate Aspirin
Use Above Median
(n ¼ 44) p Value
No. of physicians 8.0 (2.0–17.0) 13.0 (6.5–22.5) 0.04
No. of providers 9.0 (2.0–17.0) 15.0 (6.5–27.5) 0.03
Months of PINNACLE registry
participation
15.6 (7.7–36.1) 23.8 (13.7–45.4) 0.03
Practice location 0.77
Urban 31 (79.5%) 32 (82.1%)
Rural 8 (20.5%) 7 (17.9%)
Values are median (interquartile range) or n (%). Data are from sites with >30 patients receiving aspirin for
primary cardiovascular disease prevention (87 practices).
PINNACLE ¼ Practice Innovation and Clinical Excellence.
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117Approximately 36% of the adult U.S. population
(>50 million people) take aspirin regularly for CVD
prevention (20). In patients with pre-existing CVD,
the beneﬁts of aspirin use for prevention of MI,
stroke, and cardiovascular death are well estab-
lished, with >90% of these patients receiving
aspirin at hospital discharge (1). However, the role
of aspirin for primary prevention of cardiovascular
events is less clear. There are patients who would be
considered high risk for adverse cardiovascular
events due to the presence of multiple cardiovas-
cular risk factors in whom the beneﬁt of aspirin in
preventing cardiovascular events would potentially
outweigh bleeding risk. However, patients who are
at low risk for cardiovascular events could be
harmed by aspirin use due to an increased risk of
major bleeding.
For deﬁning the cutoff beneﬁt with use of aspirin
for primary CVD prevention, we used multiple
guideline recommendations on aspirin use for pri-
mary CVD prevention (4,6,7) and ascertained the
most conservative cutoff for inappropriate use from
these guidelines as 10-year CVD risk <6%. Because
women’s risk for ischemic stroke typically exceeds
their CHD risk, we evaluated the 10-year CVD risk
(as opposed to a CHD risk calculator) in all patients
by using the Framingham general CVD risk calcu-
lator. It could be argued that the Framingham risk
score was developed and validated in epidemiologic
cohorts derived from the general population and
thus has inherent limitations in its application to
patients receiving care in cardiology practices. Car-
diovascular practices enrolling patients in the
PINNACLE registry are more likely to manage pa-
tients with CVD or those with increased risk of CVD.
However, we stipulate that after excluding patients
with CVD (as we did in the present study), patients
seeking care for primary CVD prevention in a U.S.
cardiology practice should be treated in a manner
similar to a patient seeking care for the same reason
in a primary care practice. This care would entail
assessing a patient’s 10-year CVD risk followed by
instituting appropriate therapy to mitigate that
risk. Furthermore, because 72.9% of our patients
had missing variables to ascertain 10-year CVD risk,
it is possible that cardiologists may be precondi-
tioned to seeing patients with a high burden of CVD
and thus have a low threshold to use aspirin for
primary CVD prevention, which at times may be
inappropriate.
The anti-ischemic beneﬁts of aspirin for primary
prevention are reportedly sex-speciﬁc (5). In women,
the beneﬁt is mainly driven by ischemic stroke reduc-
tionwith the use of aspirin. TheWomen’s Health Studyfound a signiﬁcant decrease in major cardiovascular
events, ischemic stroke, and MI in the subgroup of
women$65 years of age who were using aspirin. Thus,
the 2011 AHA update to the guideline for CVD preven-
tion in women (15) assigns aspirin use for primary
prevention a Class IIa (Level of Evidence: B) recom-
mendation for use in women $65 years of age along
with a Class III recommendation (Level of Evidence: B)
for the routine use of aspirin in healthy women <65
TABLE 3 Comparison
10-Year CVD Risk Cou
(in Whom 10-Year CV
Age, yrs
Male
Race
White
Black
Hispanic
Provider type
Physician
Nurse practitioner
Other
Insurance*
Private
Medicare
None
Comorbidities
Diabetes
Hypertension
Dyslipidemia
Tobacco use
Medications
Angiotensin-converti
inhibitor
Angiotensin receptor
Beta-blocker
Calcium channel bloc
Diuretics
Statin
Values are mean  SD or n
insurance.
Abbreviation as in Table
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118years of age. Given these recommendations, we per-
formed sensitivity analyses by excluding women $65
years of age and found similar results with respect to
the frequency and practice-level variation in inappro-
priate use of aspirin for primary prevention.
Diabetes is known to increase the risk of devel-
oping cardiovascular events 2- to 4-fold (21). The
American Diabetes Association thus recommends
aspirin for primary prevention in patients with dia-
betes who are >40 years of age and have additional
risk factors (19). However, the randomized controlled
trials of aspirin for primary prevention in patients
with diabetes have not shown a decrease in car-
diovascular events with use of aspirin (22,23). Our
sensitivity analyses after excluding diabetic patients
in our cohort produced results that are consistent
with the study’s main ﬁndings.
Another factor to consider is the increase in statin
use over time. Statins are now recommended forof Baseline Characteristics Between Included Patients (in Whom
ld Be Calculated) and Excluded Patients due to Missing Variables
D Risk Could Not Be Calculated)
Included Participants
(n ¼ 68,808)
Excluded Participants
(n ¼ 185,531) p Value
64.0  12.8 63.7  14.1 <0.001
30,459 (44.3) 80,918 (43.6) 0.003
36,470 (88.7) 87,135 (88.5) 0.335
4,128 (10.0) 9,578 (9.7) 0.076
750 (2.8) 1,998 (3.8) <0.001
<0.001
65,379 (96.4) 173,171 (96.7)
1,930 (2.8) 4,609 (2.6)
490 (0.7) 1,211 (0.7)
40,791 (65.7) 103,517 (64.4) <0.001
31,597 (45.9) 83,443 (45.0) <0.001
2,760 (4.4) 5,962 (3.7) <0.001
14,097 (20.5) 35,428 (19.1) <0.001
56,506 (82.1) 139,196 (75.0) <0.001
55,601 (80.8) 89,249 (48.1) <0.001
31,655 (46.0) 81,374 (43.9) <0.001
ng enzyme 23,902 (34.7) 61,747 (33.3) <0.001
blocker 14,396 (20.9) 33,439 (18.0) <0.001
30,574 (44.4) 78,016 (42.1) <0.001
ker 14,464 (21.0) 35,844 (19.3) <0.001
25,508 (37.1) 63,648 (34.3) <0.001
40,893 (59.4) 87,609 (47.2) <0.001
(%); percentages were calculated from available data. *Patients can have >1 type of
1.primary prevention in patients at 10-year risk of
atherosclerotic CVD $7.5% according to the Amer-
ican College of Cardiology/AHA guideline on the
treatment of blood cholesterol (24). It is important
to note that most patients in the randomized
controlled trials of aspirin versus placebo for pri-
mary prevention were not receiving statin therapy.
The temporal trend of increasing statin use could
further decrease MI and ischemic stroke risk and
thereby further minimize any incremental beneﬁt
associated with aspirin therapy for primary CVD
prevention (25). In our cohort, 59.4% of patients
were receiving statin therapy. It is unclear if there is
any additional beneﬁt to using aspirin for primary
prevention in patients already receiving statin
therapy, while potentially increasing their risk of
major bleeding. However, to conﬁrm our results, a
sensitivity analysis was performed by excluding
patients receiving statin therapy, and similar results
were produced.
An additional consideration is the dosing of
aspirin for primary prevention. An association be-
tween higher doses of aspirin and an increased risk
of bleeding has been conﬁrmed in multiple studies,
whereas no similar association has been shown
between dose and anti-ischemic efﬁcacy of aspirin
(20). Thus, data are most supportive of a 75- to
100-mg daily dose of aspirin (4,20). It is possible
that some of the 7,972 patients receiving aspirin
inappropriately in our study could be receiving
higher doses. However, information on medication
dosages is not routinely collected in the PINNACLE
registry, and we were therefore unable to evaluate
the appropriateness of aspirin doses in our patient
population.
Our results have important implications for
quality measurement and improvement. As noted by
an Institute of Medicine (IOM) report (26), effective
care delivery denotes “providing services based on
scientiﬁc knowledge to all who could beneﬁt and
refraining from providing services to those not
likely to beneﬁt.” Although most current perfor-
mance measures incorporate measures of care de-
livery in those likely to beneﬁt from a particular
therapy (e.g., provision of aspirin or statins in pa-
tients with coronary artery disease), our results
indicate that measures that pertain to refraining
from providing therapy to those not likely to beneﬁt
or those who could be harmed by a particular
therapy are also needed to capture this important
aspect of care.
The AHA/American College of Cardiology Founda-
tion 2009 performance measures for the primary
prevention of CVD in adults have designated aspirin
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119use for internal quality improvement but not for
accountability and public reporting (2). They recom-
mended that a 10-year CVD risk assessment with a
risk score be conducted in all adults $40 years of
age every 5 years. In the present study, we were
unable to calculate the 10-year CVD risk in 185,531
(72.9%) patients receiving aspirin for primary pre-
vention mainly due to missing cholesterol values in
96.9% of these patients. To address this important
issue, we compared the baseline characteristics
between included patients (in whom 10-year CVD
risk could be calculated) and patients excluded due
to missing variables (in whom 10-year CVD risk
could not be calculated) (Table 3). Overall, these 2
groups were numerically comparable except that
patients with missing variables were less likely to
have hypertension and dyslipidemia. These results
indicate that if 10-year CVD risk had been available,
then the calculated 10-year CVD risk may have
been slightly lower in these excluded patients
compared with those included, thereby potentially
increasing the frequency of inappropriate aspirin
use even further. These analyses also suggest that
there is much work to be done to educate practi-
tioners and practices about the need to ascertain
risk by using well-validated methods before initiating
medications, such as aspirin, for primary CVD
prevention.
Of note, there was a signiﬁcant difference between
practices above and below the median practice-level
frequency of inappropriate aspirin use with respect
to their duration of participation in the PINNACLE
registry. The mean duration of participation in the
PINNACLE registry was higher (23.8 months) for
practices above the median practice-level frequency
of inappropriate aspirin use compared with those
practices that were below the median practice-level
frequency of inappropriate use (15.6 months). This
ﬁnding suggests a lack of audit and feedback to
practices with higher inappropriate aspirin use.
Future efforts that focus on incorporating the
delivery of both appropriate and inappropriate
evidence-based management of CVD risk factors
could address this gap. In addition, because aspirin is
available over the counter, patient and public edu-
cation (similar to the U.S. Food and Drug Adminis-
tration advisory against the general use of aspirin for
primary CVD prevention) will play a key role in
avoiding inappropriate use.
Finally, there is a suggestion that aspirin could be
used for the prevention of colorectal cancer and to
decrease mortality from colorectal cancer (27,28).
However, the U.S. Preventive Services Task Forcerecommends against routine use of aspirin to prevent
colorectal cancer in those at average risk for this
disease (29). Some clinicians may be more convinced
by the available evidence of the non-CVD beneﬁts
of aspirin, which could also partially explain the
practice-level variations in aspirin use.
STUDY LIMITATIONS. First, aspirin use for primary
prevention was self-reported. Because aspirin is
available over the counter with no need for pre-
scriptions, aspirin use could be underreported, and
the rates of inappropriate use in patients with 10-year
risk for CVD <6% could be higher. Second, our study
was conducted among cardiology practices partici-
pating in the PINNACLE registry. Therefore, these
practices may be highly motivated for quality
improvement, and the rates of inappropriate use of
aspirin for primary prevention could be higher in
nonparticipating practices. Furthermore, the majority
of patients seek preventative care for CVD in primary
care practices, where the frequency of inappropriate
aspirin use may be different. Third, we did not
examine ischemic or bleeding outcomes associated
with the inappropriate use of aspirin for primary
prevention in this study because those outcomes are
not routinely collected in the PINNACLE registry.
Fourth, the dose of aspirin was not collected in
the registry, and analysis pertaining to aspirin dose
could therefore not be performed. Fifth, due to
missing variables (mainly missing cholesterol values),
we were unable to calculate the 10-year CVD risk
in 72.9% of patients receiving aspirin for primary
prevention, although our analyses comparing pa-
tients who had missing and nonmissing data show
broadly comparable populations. Finally, because
aspirin is available over the counter, patient (rather
than provider) preferences could be partly driving
inappropriate use of aspirin for primary CVD
prevention.
CONCLUSIONS
More than 1 in 10 patients in this national registry
were inappropriately receiving aspirin for primary
CVD prevention, with signiﬁcant variation observed
across practices. Our ﬁndings suggest that there are
important opportunities to improve evidence-based
use of aspirin for primary CVD prevention.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Aspirin
use for primary prevention of CVD must consider several
clinical factors, including the patient’s overall risk of harm
and beneﬁt. Aspirin use is indicated for primary preven-
tion in patients with 10-year CVD risk $6% to 10%.
COMPETENCY IN INTERPERSONAL & COMMUNI-
CATION SKILLS: Because aspirin is available over the
counter, patient choice (rather than provider recommen-
dation) may be contributing to inappropriate aspirin use
for primary prevention. It is important to discuss the risks
and beneﬁts of aspirin use with patients.
TRANSLATIONAL OUTLOOK 1: Additional research
in methods to decrease practice-level variation and
prevent inappropriate aspirin use for primary prevention
in patients with low 10-year CVD risk needs to be
conducted.
TRANSLATIONAL OUTLOOK 2: The beneﬁt of aspirin
use for the primary prevention of CVD in patients
receiving statin therapy must be evaluated.
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